Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Symposium 2: When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes

Tue, Nov 17, 2026 · 8:30–9:10 AM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Presentations: (1) Spatial Determinants of Posdinemab's Effect on Tau PET; (2) CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial; (3) Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial.

Speakers